Year End Biotech Rally on Schedule

Seasonality, deals and “healthcare reform lite” spur rally On November 18 we suggested some rebalancing in the Rayno Life Science Portfolio anticipating some year-end optimism.Today we got some help from licensing M&A and financing deals. http://seekingalpha.com/article/179029-this-week-s-biotech-deal-making-and-financing?source=yahoo Moreover. the dreaded healthcare reform cloud proved to be less threatening to many sectors of the healthcare market as […]

Continue Reading 0

Sequenom down 7.5% on Xenomics’ power play

Well known biotech executives “face-off” in Licensing Deal gone awry Xenomics'(XNOM.PK) announced today that an ongoing internal preliminary investigation concluded that Sequenom (SQNM) willfully manipulated its Down Syndrome data in its presentations.In late October 2008 Xenomics granted an exclusive license to Sequenom for its transrenal technology based upon Sequenom’s announced success in developing a Down […]

Continue Reading 0

H1N1 Boosts Development in Pharma Sector

Global market growth for vaccines forecasted at 12% ( Edited version published in Genetic Engineering News Dec. 1, 2009) The potential H1N1pandemic has drawn renewed interest in vaccines. Vaccines over the last 100+ years have been one of the most important agents for controlling infectious disease beginning with smallpox then polio in the fifties. From […]

Continue Reading 0

Positioning for a possible year-end Biotech Rally

After a nasty October correction of 10%, biotech stocks are in a recovery mode and poised for a Q4 rally extending to early January. This trend was intact in the past (check ’05,’06, and ’07 trends) but was disrupted by the recent financial crisis of ‘08/09. A nice base has formed around the IBB level […]

Continue Reading 0

Biotech stock rally continues: mid caps up 2.5%

Biotech stocks continue to rally off the early November bottom despite bad news from Poniard (PARD) because of the picoplatin study failure. PARD was down 76% at 12:09p. The recent news of Sanofi-Aventis adding $800M in funding of Regeneron for monoclonal antibody therapeutics has bolstered the market. The IBB is up 6.5% off the intermediate […]

Continue Reading 0

Biotech sell-off abating

The technicals in the biotech market are looking a lot better but the damage from October was severe. The 10% correction from the Sep 21, 2009 peak is about over as long as the NASDAQ holds up. The IBB is at 75 today off its high of 84. Good news from a number of companies […]

Continue Reading 0

Biotech sell-off continues

We commented on Tuesday about the broad selling of all biotech stocks large and small and this trend continues through today. AMGN shares are down this week despite earnings EPS of $1.49 beating estimates of $1.27 as regulatory concerns about its experimental osteoporosis drug weighed on investor.Despite bullish analyst support and a forecast of approval […]

Continue Reading 0

Biotech stocks in stealth retreat

Biotech stocks were in a broad retreat today for reasons that are not yet apparent as the Nasdaq and S&P were only down a modest 0.6%. Large caps that were hard hit include AMGN, BIIB,and VRTX as well as the major ETF’s IBB and XBI. My broad index of 35 mid cap biotechs was down […]

Continue Reading 0

Life Science Market Performance Q3 2009

Biotech summer rally sparked by deals Life Science stocks kept pace with market sectors that offer comparable risk and performance: Small cap growth, science and technology and midcap growth. The bellwether, broadly diversified ETF IBB was up 16% moving from 70 to 81 in the three month period. About 50% of the IBB holdings are […]

Continue Reading 0

H1N1 Swine Flu activity picks up; vaccine roll-out underway

The CDC provided a situation update regarding key flu indicators for the Week of Sep 20-26 and said that influenza activity remained elevated in virtually all states. Visits to doctors and hospitals are higher than can be expected this time of the year and almost all cases were similar to the H1N1 strain which was […]

Continue Reading 0